Anviro Therapeutics

Pharmaceutical, Biotech

Anviro Therapeutics (Anviro) is a broad-spectrum antiviral company that is developing treatments for some of the world’s most problematic infectious diseases, including pox viruses and herpes viruses. Our lead program is based on technology discovered by researchers at Brigham Young University (BYU). This compound, designated KPB-100, was found to have powerful antiviral properties, and efficacy across a wide range of viruses in the herpes and pox virus families. In April of 2015, Anviro licensed this technology from BYU and are in the process of medicinal optimization and animal model validation.